Company facts
- Headquarters
- New York, New York
- Most recent report
- 10-Q, filed Nov 6, 2026
- Incorporated
- N/A
- Filings on record
- 811 filings
- On EDGAR
- CIK 1359931
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company
Financials 8 of 52
News 8 of 131
Prospectuses and Registrations 8 of 47
- S-8 Registration statement for an employee plan Aug 11, 2026
- 424B5 Prospectus supplement for an offering May 28, 2026
- S-3 Shelf registration statement May 14, 2026
- 424B5 Prospectus supplement for an offering Dec 5, 2025
- 424B5 Prospectus supplement for an offering Dec 4, 2025
- S-8 Registration statement for an employee plan Aug 11, 2025
- S-8 Registration statement for an employee plan Mar 5, 2025
- 424B5 Prospectus supplement for an offering Dec 11, 2024
Proxies 8 of 23
- DEFA14A Extra proxy material Apr 28, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 28, 2026
- PRE 14A Preliminary proxy statement Apr 17, 2026
- DEFA14A Extra proxy material Apr 25, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 25, 2025
- DEFA14A Extra proxy material Apr 26, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 26, 2024
- DEFA14A Extra proxy material Apr 26, 2023
Ownership 8 of 474
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 13, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Jul 7, 2026
- 4 Insider reported a trade Jul 1, 2026
- 144 Notice of a proposed sale of restricted stock Jun 29, 2026
- 4 Insider reported a trade Jun 16, 2026
- 4 Insider reported a trade Jun 16, 2026
- 4 Insider reported a trade Jun 16, 2026
- 4 Insider reported a trade Jun 16, 2026
Other 8 of 84
Everything here comes from Protara Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.